The company intends to use the capital, whose amount was not disclosed, to advance its biomarker test kit for rheumatoid arthritis treatment. A proof of concept is already in place for the antibody-based verification procedure in an ELISA format (Enzyme Linked Immunosorbent Assay). The required biomarkers can also already be produced in high technical quality and fairly large quantities.